MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ibd/izad018

Медицинская библиотека · Inflammatory bowel diseases · 2024

Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease.

Bramuzzo Matteo, Giudici Fabiola, Arrigo Serena, Lionetti Paolo, Zuin Giovanna, Romano Claudio, Graziano Francesco, Faraci Simona, Alvisi Patrizia, Signa Sara, Scarallo Luca, Martelossi Stefano, Di Leo Grazia

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Few drugs have been studied for patients with very early onset inflammatory bowel disease (VEOIBD). This study aimed to evaluate the efficacy and tolerance of thalidomide in children with VEOIBD compared with children with pediatric-onset IBD (pIBD).

METHODS

A retrospective cohort study with a control group was conducted. Propensity score 1:1 matching was used to identify control subjects. The treatment persistence; the causes of drug withdrawal; the rate of clinical remission and mucosal healing at 1, 2, and 3 years; and adverse events (AEs) were evaluated in children with VEOIBD treated with thalidomide and compared with children with pIBD.

RESULTS

Thirty-nine courses of treatment with thalidomide in VEOIBD and pIBD patients were compared. The treatment persistence at 1, 2, and 3 years was 68.2% (95% confidence interval [CI], 50.8%-80.6%), 57.0% (95% CI, 39.6%-71.1%), and 50.9% (95% CI, 33.7%-65.8%) for VEOIBD patients and 81.7% (95% CI, 65.3%-90.9%), 60.0% (95% CI, 41.7%-74.3%) and 33.0% (95% CI, 17.4%-49.5%) for pIBD patients, respectively (P = .12). A significantly higher proportion of VEOIBD patients discontinued therapy due to lack of efficacy (48.2% vs 17.2%; P = .03), while AEs were the main reason for discontinuation in pIBD patients. Clinical remission and mucosal healing rates did not significantly differ between VEOIBD and pIBD patients. A significatively lower number of VEOIBD patients experienced AEs compared with pIBD patients (14 [35.9%] vs 30 [76.9%]; P = .0005).

CONCLUSIONS

Thalidomide is an effective and tolerated treatment in children with VEOIBD. Discontinuation due to lack of efficacy is more frequent, but AEs are less common than in children with pIBD.

Для цитирования: Bramuzzo Matteo, Giudici Fabiola, Arrigo Serena, Lionetti Paolo, Zuin Giovanna, Romano Claudio, Graziano Francesco, Faraci Simona, Alvisi Patrizia, Signa Sara, Scarallo Luca, Martelossi Stefano, Di Leo Grazia. Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease.. Inflammatory bowel diseases. 2024. DOI: 10.1093/ibd/izad018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.